Law
Cryoviva Advocates for ATMP Legislation to Boost Thailand’s Medical Hub Status
Cryoviva, a Thai stem cell bank, is pushing for the implementation of Advanced Therapy Medicinal Products (ATMP) regulations to align with global medical trends.
According to a report by Prachachat Business, Cryoviva, the only stem cell bank in Thailand, participated in a discussion regarding Advanced Therapy Medicinal Products (ATMP) legislation during the MEP3 event. The company highlighted that the global market for advanced medical therapies is projected to reach $61.5 billion by 2030.
Cryoviva has proposed that the public and private sectors collaborate to establish standardized traceability protocols. The company suggests that such regulatory frameworks are essential for Thailand to solidify its position as a regional medical hub. ATMPs represent a specialized field of medicine involving gene therapy, somatic cell therapy, and tissue-engineered products.
For residents and medical tourists in Thailand, this development is significant as it signals a potential shift toward more rigorous oversight and standardized quality control in advanced medical treatments. If adopted, these regulations could influence the availability and safety standards of cutting-edge therapies within the country.
However, it remains to be confirmed how the Thai government will respond to these specific policy proposals and what the timeline for drafting or enacting formal ATMP legislation might be. As of now, the discussion remains at the proposal stage, and no official changes to current medical regulations have been enacted.
Translated from Thai.
SawaLife is not a news organisation. We classify and translate source material using automated processing and editorial controls; the original publication remains the authoritative context.